2007Yixue fenzi shengwuxue zazhiRequires access

Influence of VKORC1-1639G/A and CYP2C9 1061A/C Polymorphisms on Warfarin Dose

Xiaoying Wu

Open publisher page 2 citations

Abstract

Objective To investigate the influence of VKORC1-1639 G/A and CYP2C9 1061 A/C polymorphisms on warfarin dose in Chinese patients of Han nationality.Methods PCR-RFLP technique was used to genotype the VKORC1-1639 G/A and CYP2C9 1061 A/C polymorphisms of 129 warfarin-treated patients.The mean warfarin doses used for the patients with different VKORC1 and CYP2C9 genotypes were compared.Results The frequencies of the VKORC1-1639 AA,AG,GG genotypes in the patient group were 74.4 %(96),23.3 %(30)and 2.3 %(3),respectively;allele frequencies were 86% for VKORC1-1639 A and 14 % for G;frequencies of the CYP2C9 1061 AA,AC,CC genotypes were 90.7 %(117),8.5 %(11)and 0.8(1),respectively;allele frequencies were 95% for CYP2C9 1061 A and 5% for C.There were no significant difference in genotype distribution of VKORC1-1639 and CYP2C9 1061 between the patients and the healthy controls(χ2=2.614,P=0.265;χ2=2.493,P=0.259,respectively).The mean warfarin dose differed significantly among the VKORC1 genotypes(P0.001);the patients carrying VKORC1-1639 AA genotype had a lower mean warfarin dose(1.444±0.282 mg/INR)compared with those carring AG genogype(1.629±0.258 mg/INR)(P=0.02),and the mean warfarin dose of the patients with AG genotype was lower than those with GG genotype[(2.031±0.087)mg/INR,P=0.017].The carriers of CYP2C9 1061 C allele(AC+CC)had a lower warfarin dose(1.328±0.185 mg/INR)than those with CYP2C9 1061 AA genotype[(1.518±0.299)mg/INR,P=0.032].Conclusion There might be an association between VKORC1-1639 G→A,CYP2C9 1061 A→C transformation and decreased warfarin dose and the major genotype of VKORC1-1639(AA)might account for the universally lower warfarin dosage used in Chinese Han population.

About this research paper

What this paper is about

Objective To investigate the influence of VKORC1-1639 G/A and CYP2C9 1061 A/C polymorphisms on warfarin dose in Chinese patients of Han nationality.Methods PCR-RFLP technique was used to genotype the VKORC1-1639 G/A and CYP2C9 1061 A/C polymorphisms of 129 warfarin-treated patients.The mean warfarin doses used for the patients with different VKORC1 and CYP2C9 genotypes were compared.Results The frequencies of the VKORC1-1639 AA,AG,GG genotypes in the patient group were 74.4 %(96),23.3 %(30)and 2.3 %(3),respectively;allele frequencies were 86% for VKORC1-1639 A and 14 % for G;frequencies of the CYP2C9 1061 AA,AC,CC genotypes were 90.7 %(117),8.5 %(11)and 0.8(1),respectively;allele frequencies were 95% for CYP2C9 1061 A and 5% for C.There were no significant difference in genotype distribution of VKORC1-1639 and CYP2C9 1061 between the patients and the healthy controls(χ2=2.614,P=0.265;χ2=2.493,P=0.259,respectively).The mean warfarin dose differed significantly among the VKORC1 genotypes(P0.001);the patients carrying VKORC1-1639 AA genotype had a lower mean warfarin dose(1.444±0.282 mg/INR)compared with those carring AG genogype(1.629±0.258 mg/INR)(P=0.02),and the mean warfarin dose of the patients with AG genotype was lower than those with GG genotype[(2.031±0.087)mg/INR,P=0.017].The carriers of CYP2C9 1061 C allele(AC+CC)had a lower warfarin dose(1.328±0.185 mg/INR)than those with CYP2C9 1061 AA genotype[(1.518±0.299)mg/INR,P=0.032].Conclusion There might be an association between VKORC1-1639 G→A,CYP2C9 1061 A→C transformation and decreased warfarin dose and the major genotype of VKORC1-1639(AA)might account for the universally lower warfarin dosage used in Chinese Han population.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To investigate the influence of VKORC1-1639 G/A and CYP2C9 1061 A/C polymorphisms on warfarin dose in Chinese patients of Han nationality.Methods PCR-RFLP technique was used to genotype the VKORC1-1639 G/A and CYP2C9 1061 A/C polymorphisms of 129 warfarin-treated patients.The mean warfarin doses used for the patients with different VKORC1 and CYP2C9 genotypes were compared.Results The frequencies of the VKORC1-1639 AA,AG,GG genotypes in the patient group were 74.4 %(96),23.3 %(30)and 2.3 %(3),respectively;allele frequencies were 86% for VKORC1-1639 A and 14 % for G;frequencies of the CYP2C9 1061 AA,AC,CC genotypes were 90.7 %(117),8.5 %(11)and 0.8(1),respectively;allele frequencies were 95% for CYP2C9 1061 A and 5% for C.There were no significant difference in genotype distribution of VKORC1-1639 and CYP2C9 1061 between the patients and the healthy controls(χ2=2.614,P=0.265;χ2=2.493,P=0.259,respectively).The mean warfarin dose differed significantly among the VKORC1 genotypes(P0.001);the patients carrying VKORC1-1639 AA genotype had a lower mean warfarin dose(1.444±0.282 mg/INR)compared with those carring AG genogype(1.629±0.258 mg/INR)(P=0.02),and the mean warfarin dose of the patients with AG genotype was lower than those with GG genotype[(2.031±0.087)mg/INR,P=0.017].The carriers of CYP2C9 1061 C allele(AC+CC)had a lower warfarin dose(1.328±0.185 mg/INR)than those with CYP2C9 1061 AA genotype[(1.518±0.299)mg/INR,P=0.032].Conclusion There might be an association between VKORC1-1639 G→A,CYP2C9 1061 A→C transformation and decreased warfarin dose and the major genotype of VKORC1-1639(AA)might account for the universally lower warfarin dosage used in Chinese Han population.

Key concepts: VKORC1, CYP2C9, Warfarin, Genotype, Internal medicine, Vitamin K epoxide reductase, Gastroenterology, Allele

Related papers

Back to paper searchBrowse research topicsOriginal source
Influence of VKORC1-1639G/A and CYP2C9 1061A/C Polymorphisms on Warfarin Dose — Research Paper | ScholarLens